Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 109 of 1,261
  1. US 12023343

    Thermo-kinetic mixing for pharmaceutical applications

    The Board of Regents of the University of Texas System Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  2. US 12024556

    Anti-Staphylococcus antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  3. WO 2024133935

    EXCIPIENTS DE CONJUGAISON PROTÉIQUES

    ABLYNX NV [BE] Β· Granted Jun 27, 2024 Β· Expires Jun 22, 2044

    granted
  4. US 12018052

    Methods of detection and removal of rhabdoviruses from cell lines

    Takeda Vaccines, Inc. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  5. US 12018090

    PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

    Rani Therapeutics, LLC Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  6. US 12018027

    Macrocyclic derivatives acting as XIa factor inhibitor

    China Resources Biopharmaceutical Company Limited Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  7. US 12018043

    CD73 inhibitors

    ORIC PHARMACEUTICALS, INC. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  8. US 12018057

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Protagonist Therapeutics, Inc. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  9. US 12018125

    Block-copolymers for the delivery of active agents

    Julius-Maximilians-Universitat Wurzburg Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  10. US 12017030

    Hydrogen-enhanced transdermal system

    H2 Universe LLC Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  11. US 12018135

    Encapsulation by cross-linking of anionic polymers by pH induced dissociation of cation-chelate complexes

    The Regents of the University of California Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  12. US 12018087

    Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject

    Dyne Therapeutics, Inc. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  13. US 12018255

    Compositions and methods for treating disorders of genomic imprinting

    UNIVERSITY OF CONNECTICUT Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  14. US 12018011

    Macrocyclic compounds and compositions, and methods of preparing and using the same

    Kura Oncology, Inc. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  15. US 12018261

    Compounds and methods for modulating factor XII

    Ionis Pharmaceuticals, Inc. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  16. US 12016950

    Devices and methods for treating ear pain

    Try This First, Inc. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  17. US 12016867

    Methods of treating inflammation and/or pain

    Semnur Pharmaceuticals, Inc. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  18. US 12016929

    Lipid formulations for delivery of therapeutic agents

    ARBUTUS BIOPHARMA CORPORATION Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  19. US 12018260

    Tunable Reversirβ„’ compounds

    Alnylam Pharmaceuticals, Inc. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  20. US 12018082

    Methods and agents for treating infections

    The Regents of the University of California Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  21. US 12018045

    17-beta-hydroxywithanolides and use thereof in treating cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  22. US 12016908

    Compositions and methods for treating hemoglobinopathies

    Beam Therapeutics Inc. Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  23. US 12016932

    Gene editing for hemophilia A with improved factor VIII expression

    CRISPR THERAPEUTICS AG Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted
  24. US 12017989

    Controlled release pharmaceutical formulations

    United Therapeutics Corporation Β· Granted Jun 25, 2024 Β· Expires Jun 20, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.